Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
POLICY PAPERS
April 08, 2024
The global locus of undervaccination is increasingly shifting from the poorest countries in the world—which are eligible for support from Gavi, the Vaccine Alliance—to middle-income countries (MICs) that do not qualify for traditional Gavi support. Given these growing challenges, Gavi must rethink i...
Blog Post
April 08, 2024
When Gavi, the Vaccine Alliance, was founded in 2001, it logically targeted its support to the poorest countries—with GNI per capita under a pre-defined eligibility threshold—that also had the highest shares of the world’s undervaccinated children. Fast-forward almost 25 years, and the situation has...
Blog Post
November 15, 2023
One of the most salient lessons from the pandemic is the need to diversify manufacturing capabilities and bolster supply resilience to avoid a repeat of the slow and inequitable vaccine roll out in African countries. To turn this lesson into action, the Gavi Secretariat is rapidly advancing plans fo...
Blog Post
August 16, 2023
Despite verbal nods to global cooperation, equity, and solidarity, the COVID-19 pandemic laid bare a brutal realpolitik: all countries will put their citizens first and vaccinate their own populations, before offering charitable leftovers beyond their own borders. Sub-Saharan Africa, more than any o...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
Blog Post
November 09, 2020
This morning, America (and much of the world) woke up to a snippet of terrific news: Pfizer and BioNTech announced their SARS-CoV2 vaccine candidate showed 90 percent efficacy. But for policymakers in low- and middle-income countries, today’s news offers limited cause for celebration—and the Pfizer/...